The Inhibitory Effects of New Zealand Pine Bark (Enzogenol®) on α-Amylase, α-Glucosidase, and Dipeptidyl Peptidase-4 (DPP-4) Enzymes

Nutrients

Wen Xin Janice Lim¹  Cheryl S. Gammon¹  Rachel A. Page²  Pamela von Hurst³  Lynne Chepulis⁴ 

[1] School of Health Sciences, Massey University, Auckland 0632, New Zealand;School of Health Sciences, Massey University, Wellington 6021, New Zealand;School of Sport, Exercise and Nutrition, Massey University, Auckland 0632, New Zealand;Waikato Medical Research Centre, Te Huataki Waiora School of Health, University of Waikato, Hamilton 3216, New Zealand;

关键词: functional food;    hyperglycaemia;    hypoglycaemic effects;    impaired glycaemic control;    incretin effect;    polyphenol;   

DOI  :  10.3390/nu14081596

来源: DOAJ

【 摘 要 】

The New Zealand pine bark extract (Enzogenol^®) has previously been shown to elicit acute hypoglycaemic effects in humans. The present study investigated the underlying mechanisms of Enzogenol^® in reducing postprandial glucose in humans. The potential inhibitory action of Enzogenol^® against digestive enzymes: α-amylase and α-glucosidase, and dipeptidyl peptidase-4 (DPP-4) enzyme was determined. Enzogenol^® demonstrated the ability to inhibit all three enzymes: α-amylase enzyme activity (IC₅₀ 3.98 ± 0.11 mg/mL), α-glucosidase enzyme activity (IC₅₀ 13.02 ± 0.28 μg/mL), and DPP-4 enzyme activity (IC₅₀ 2.51 ± 0.04 mg/mL). The present findings indicate the potential for Enzogenol^® to improve postprandial glycaemia by delaying carbohydrate digestion via the inhibition of digestive enzymes (α-amylase and α-glucosidase), and enhancing the incretin effect via inhibiting the dipeptidyl-peptidase-4 enzyme. The inhibitory actions of Enzogenol^® on enzymes should therefore be further validated in humans for its potential use in type 2 diabetes mellitus prevention and management.

【 授权许可】

Unknown